| [1] |
Lengyel E. Ovarian cancer development and metastasis [J]. Am J Pathol, 2010, 177(3): 1053-1064.
|
| [2] |
Kipps E, Tan DS, Kaye SB. Meeting the challenge of ascites in ovarian cancer: new avenues for therapy and research [J]. Nat Rev Cancer, 2013, 13(4): 273-282.
|
| [3] |
张菲菲，金世柱，刘自帅. 恶性腹水的治疗新观点 [J]. 胃肠病学和肝病学杂志, 2017, 26(4): 476-478.
|
| [4] |
Kim S, Kim B, Song Y. Ascites modulates cancer cell behavior, contributing to tumor heterogeneity in ovarian cancer [J]. Cancer Sci, 2016, 107(9): 1173-1178.
|
| [5] |
Matte I, Lane D, Laplante C. Profiling of cytokines in human epithelial ovarian cancer ascites [J]. Am J Cancer Res, 2012, 2(5): 566-580.
|
| [6] |
So KA, Min KJ, Hong JH. Interleukin-6 expression by interactions between gynecologic cancer cells and human mesenchymal stem cells promotes epithelial-mesenchymal transition [J]. Int J Oncol, 2015, 47(4): 1451-1459.
|
| [7] |
Kim S, Gwak H, Kim HS. Malignant ascites enhances migratory and invasive properties of ovarian cancer cells with membrane bound IL-6R in vitro [J]. Oncotarget, 2016, 7(50): 83148-83159.
|
| [8] |
Yin J, Zeng F, Wu N. Interleukin-8 promotes human ovarian cancer cell migration by epithelial-mesenchymal transition induction in vitro [J]. Clin Transl Oncol, 2015, 17(5): 365-370.
|
| [9] |
Wang Y, Xu RC, Zhang XL. Interleukin-8 secretion by ovarian cancer cells increases anchorage-independent growth, proliferation, angiogenic potential, adhesion and invasion [J]. Cytokine, 2012, 59(1): 145-155.
|
| [10] |
Matte I, Lane D, Bachvarov D. Role of malignant ascites on human mesothelial cells and their gene expression profiles [J]. BMC Cancer, 2014, 14: 288.
|
| [11] |
Lane D, Matte I, Rancourt C. Osteoprotegerin (OPG) protects ovarian cancer cells from TRAIL-induced apoptosis but does not contribute to malignant ascites-mediated attenuation of TRAIL-induced apoptosis [J]. J Ovarian Res, 2012, 5(1): 34.
|
| [12] |
Lane D, Matte I, Laplante C. CCL18 from ascites promotes ovarian cancer cell migration through proline-rich tyrosine kinase 2 signaling [J]. Mol Cancer, 2016, 15(1): 58.
|
| [13] |
Biskup K, Braicu EI, Sehouli J. The ascites N-glycome of epithelial ovarian cancer patients [J]. J Proteomics, 2017, 157: 33-39.
|
| [14] |
Yunusova NV, Villert AB, Spirina LV. Insulin-Like Growth Factors and Their Binding Proteins in Tumors and Ascites of Ovarian Cancer Patients: Association With Response To Neoadjuvant Chemotherapy [J]. Asian Pac J Cancer Prev, 2016, 17(12): 5315-5320.
|
| [15] |
Saltzman AK, Hartenbach EM, Carter JR. Transforming growth factor-alpha levels in the serum and ascites of patients with advanced epithelial ovarian cancer [J]. Gynecol Obstet Invest, 1999, 47(3): 200-204.
|
| [16] |
Abendstein B, Stadlmann S, Knabbe C. Regulation of transforming growth factor-beta secretion by human peritoneal mesothelial and ovarian carcinoma cells [J]. Cytokine, 2000, 12(7): 1115-1119.
|
| [17] |
Shender VO, Pavlyukov MS, Ziganshin RH. Proteome-metabolome profiling of ovarian cancer ascites reveals novel components involved in intercellular communication [J]. Mol Cell Proteomics, 2014, 13(12): 3558-3571.
|
| [18] |
Senger DR, Galli SJ, Dvorak AM. Tumor cells secrete a vascular permeability factor that promotes accumulation of ascites fluid [J]. Science, 1983, 219(4587): 983-985.
|
| [19] |
杨娜，陈琦. 血管内皮生长因子及其受体与卵巢癌相关性的研究进展 [J]. 中国老年学杂志, 2017, 37(2): 491-494.
|
| [20] |
Ahmed N, Stenvers KL. Getting to know ovarian cancer ascites: opportunities for targeted therapy-based translational research [J]. Front Oncol, 2013, 3: 256.
|
| [21] |
苏杭，胡冰. 恶性腹腔积液的靶向治疗进展 [J]. 医药导报, 2016, 35(5): 496-500.
|
| [22] |
Byrne AT, Ross L, Holash J. Vascular endothelial growth factor-trap decreases tumor burden, inhibits ascites, and causes dramatic vascular remodeling in an ovarian cancer model [J]. Clin Cancer Res, 2003, 9(15): 5721-5728.
|
| [23] |
Yukita A, Asano M, Okamoto T. Suppression of ascites formation and re-accumulation associated with human ovarian cancer by an anti-VPF monoclonal antibody in vivo [J]. Anticancer Res, 2000, 20(1a): 155-160.
|
| [24] |
Bamias A, Koutsoukou V, Terpos E. Correlation of NK T-like CD3＋CD56＋ cells and CD4＋CD25＋(hi) regulatory T cells with VEGF and TNFalpha in ascites from advanced ovarian cancer: Association with platinum resistance and prognosis in patients receiving first-line, platinum-based chemotherapy [J]. Gynecol Oncol, 2008, 108(2): 421-427.
|
| [25] |
Santin AD, Hermonat PL, Ravaggi A. Secretion of vascular endothelial growth factor in ovarian cancer [J]. Eur J Gynaecol Oncol, 1999, 20(3): 177-181.
|
| [26] |
夏红慧，詹娜. 卵巢癌腹水中血管内皮生长因子的表达及临床意义 [J]. 中国生育健康杂志, 2016, 27(2): 127-129.
|
| [27] |
Zhan N, Dong WG, Wang J. The clinical significance of vascular endothelial growth factor in malignant ascites [J]. Tumour Biol, 2016, 37(3): 3719-3725.
|
| [28] |
张庆松，李燕华. 贝伐单抗在卵巢癌中的应用进展 [J]. 肿瘤学杂志, 2016, 22(4): 310-315.
|
| [29] |
Hamilton CA, Maxwell GL, Chernofsky MR. Intraperitoneal bevacizumab for the palliation of malignant ascites in refractory ovarian cancer [J]. Gynecol Oncol, 2008, 111(3): 530-532.
|
| [30] |
Belotti D, Paganoni P, Manenti L. Matrix metalloproteinases (MMP9 and MMP2) induce the release of vascular endothelial growth factor (VEGF) by ovarian carcinoma cells: implications for ascites formation [J]. Cancer Res, 2003, 63(17): 5224-5229.
|
| [31] |
毛柳. 卵巢癌腹水及外周血CD4~＋CD25~＋Treg/CD4~＋T细胞含量及其意义分析 [J]. 中国妇幼保健, 2016, 31(22): 4871-4874.
|
| [32] |
Zhang Y, Chen Q. Relationship between matrix metalloproteinases and the occurrence and development of ovarian cancer [J]. Braz J Med Biol Res, 2017, 50(6): e6104.
|
| [33] |
Jesionowska A, Cecerska-Heryc E, Matoszka N. Lysophosphatidic acid signaling in ovarian cancer [J]. J Recept Signal Transduct Res, 2015, 35(6): 578-584.
|
| [34] |
Li H, Wang D, Zhang H. Lysophosphatidic acid stimulates cell migration, invasion, and colony formation as well as tumorigenesis/metastasis of mouse ovarian cancer in immunocompetent mice [J]. Mol Cancer Ther, 2009, 8(6): 1692-1701.
|
| [35] |
唐慧，伍海姗，杨怡. 外泌体源性microRNA在疾病诊疗中的研究进展 [J]. 中南大学学报(医学版), 2015, 40(11): 1270-1275.
|
| [36] |
邹玉鹏，李力. 卵巢癌血清新型肿瘤标志物研究与应用现况 [J]. 肿瘤防治研究, 2017, 44(9): 631-635.
|
| [37] |
Barni S, Cabiddu M, Ghilardi M. A novel perspective for an orphan problem: old and new drugs for the medical management of malignant ascites [J]. Crit Rev Oncol Hematol, 2011, 79(2): 144-153.
|
| [38] |
李岩，胡冰. 恶性腹水的抗血管生成治疗进展 [J]. 安徽医药, 2013, 17(4): 541-543.
|
| [39] |
Puiffe ML, Le PC, Filali-Mouhim A. Characterization of ovarian cancer ascites on cell invasion, proliferation, spheroid formation, and gene expression in an in vitro model of epithelial ovarian cancer [J]. Neoplasia, 2007, 9(10): 820-829.
|
| [40] |
Meunier L, Puiffe ML, Le PC. Effect of ovarian cancer ascites on cell migration and gene expression in an epithelial ovarian cancer in vitro model [J]. Transl Oncol, 2010, 3(4): 230-238.
|
| [41] |
Cohen M, Pierredon S, Wuillemin C. Acellular fraction of ovarian cancer ascites induce apoptosis by activating JNK and inducing BRCA1, Fas and FasL expression in ovarian cancer cells [J]. Oncoscience, 2014, 1(4): 262-271.
|
| [42] |
Lane D, Goncharenko-Khaider N, Rancourt C. Ovarian cancer ascites protects from TRAIL-induced cell death through alphavbeta5 integrin-mediated focal adhesion kinase and Akt activation [J]. Oncogene, 2010, 29(24): 3519-3531.
|
| [43] |
Lane D, Matte I, Rancourt C. The prosurvival activity of ascites against TRAIL is associated with a shorter disease-free interval in patients with ovarian cancer [J]. J Ovarian Res, 2010, 3: 1.
|
| [44] |
Lane D, Robert V, Grondin R. Malignant ascites protect against TRAIL-induced apoptosis by activating the PI3K/Akt pathway in human ovarian carcinoma cells [J]. Int J Cancer, 2007, 121(6): 1227-1237.
|
| [45] |
Ueda T, Maehara M, Takahashi Y. Clinical significance of cell-free and concentrated ascites re-infusion therapy for advanced and recurrent gynecological cancer [J]. Anticancer Res, 2012, 32(6): 2353-2357.
|
| [46] |
曾凡清，吴南顺，殷娟. 紫杉醇联合卡铂不同给药途径治疗卵巢癌的疗效观察 [J]. 中国药业, 2015, 24(23): 171-172.
|
| [47] |
吴国芳，刘丽. 顺铂不同给药途径联合紫杉醇静脉滴注治疗晚期卵巢癌的疗效和不良反应 [J]. 中国肿瘤临床与康复, 2016, 23(3): 300-302.
|
| [48] |
Nicoletto MO, Casarin A, Baldoni A. Intraperitoneal chemotherapy in patients pretreated for ovarian cancer matched with patients treated with parenteral chemotherapy [J]. Anticancer Res, 2016, 36(12): 6541-6546.
|